https://mugglehead.com/summit-therapeutics-ivonescimab-biliary-cancer-survival-china/ Mugglehead Media en 2026-10-25T16:17:15.813Z Summit Therapeutics reports 25% lower death risk in biliary-cancer trial NASDAQ: SMMT, HKG: 9926, LON: AZN, NYSE: AZN, Summit Therapeutics, Akeso, AstraZeneca, Biliary tract cancer, Phase 3, Ivonescimab https://mugglehead.com/biontech-bristol-myers-pumitamig-second-line-lung-cancer-phase-2/ Mugglehead Media en 2026-10-25T13:49:46.462Z BioNTech and Bristol Myers report 36.7% response in lung-cancer trial NASDAQ: BNTX, NYSE: BMY, NYSE: LLY, NASDAQ: IBB, BioNTech SE, Bristol Myers Squibb, Eli Lilly and Company, Lung cancer, Phase 2, Immunotherapy https://mugglehead.com/xencor-xmab819-kidney-cancer-dose-response-safety/ Mugglehead Media en 2026-10-25T12:46:07.052Z Xencor reports 45.5% confirmed response at selected kidney-cancer dose NASDAQ: XNCR, NYSE: MRK, NASDAQ: EXEL, Xencor, Merck, Exelixis, Kidney cancer, Phase 1, Bispecific antibodies, Clinical trials https://mugglehead.com/genmab-petosemtamab-colorectal-phase-2-response-follow-up/ Mugglehead Media en 2026-10-25T11:44:53.410Z Genmab reports 75% first-line response in petosemtamab colorectal study NASDAQ: GMAB, NASDAQ: INCY, NASDAQ: IBB, Genmab A/S, Incyte Corporation, iShares Biotechnology ETF, Colorectal cancer, Phase 2, Antibodies, ESMO https://mugglehead.com/lilly-olomorasib-first-line-lung-cancer-response-duration/ Mugglehead Media en 2026-10-25T11:14:43.762Z Lilly reports 14.5-month response duration with olomorasib lung-cancer combination NYSE: LLY, NASDAQ: AMGN, NASDAQ: IBB, Eli Lilly and Company, Amgen Inc, iShares Biotechnology ETF, Lung cancer, KRAS G12C, Clinical trials, Phase 3 https://mugglehead.com/canopy-growth-shareholders-authorize-reverse-stock-split/ Mugglehead Media en 2026-10-25T00:32:27.119Z Canopy Growth Corporation shareholders authorize up to 1-for-15 reverse split TSE: WEED, NASDAQ: CGC, TSE: TLRY, NASDAQ: TLRY, Canopy Growth Corporation, Tilray Brands, Reverse stock split, Shareholder vote, Nasdaq https://mugglehead.com/climb-bio-budoprutug-prismn-kidney-phase-2-data/ Mugglehead Media en 2026-10-24T23:59:00.074Z Climb Bio reports 38% immunologic remission in kidney trial NASDAQ: CLYM, NASDAQ: BIIB, SWX: ROP, OTCMKTS: RHHBY, NASDAQ: IBB, Climb Bio, Biogen, Roche, Phase 2, Kidney disease https://mugglehead.com/teck-resources-highland-valley-copper-strike-reduced-capacity/ Mugglehead Media en 2026-10-24T19:43:21.830Z Teck Resources reports reduced capacity at Highland Valley as strike begins TSE: TECK.A, TSE: TECK.B, NYSE: TECK, Teck Resources Limited, Copper, Labour action, British Columbia https://mugglehead.com/sterlite-technologies-revenue-hyperscaler-supply-agreements/ Mugglehead Media en 2026-10-24T18:18:56.896Z Sterlite Technologies reports INR25.29B revenue and multiyear supply deals NSE: STLTECH, BOM: 532374, HEL: NOKIA, NYSE: NOK, Sterlite Technologies Limited, Nokia Corporation, Optical connectivity, AI infrastructure, Quarterly earnings, Supply agreements https://mugglehead.com/genmab-incyte-colorectal-cancer-combination-trial/ Mugglehead Media en 2026-10-24T18:07:13.113Z Genmab and Incyte agree to colorectal cancer combination trial NASDAQ: GMAB, NASDAQ: INCY, NASDAQ: RVMD, NASDAQ: IBB, Genmab A/S, Incyte Corporation, Revolution Medicines, iShares Biotechnology ETF, Colorectal cancer, Clinical trials https://mugglehead.com/alphabet-google-voltus-virtual-power-plant-pjm/ Mugglehead Media en 2026-10-24T17:45:52.121Z Alphabet's Google expands Voltus virtual power plant agreement to 1 GW NASDAQ: GOOGL, NASDAQ: GOOG, NASDAQ: RUN, Alphabet Inc, Google, Voltus, Sunrun Inc, Virtual power plants, Demand response, Data centres https://mugglehead.com/pfizer-25-strain-infant-pneumococcal-vaccine-phase-2/ Mugglehead Media en 2026-10-24T16:37:07.500Z Pfizer details 25-strain infant vaccine data as pivotal trials advance NYSE: PFE, NYSE: MRK, Pfizer, Merck & Co., Vaccines, Pneumococcal disease, Phase 2, Phase 3 https://mugglehead.com/bitdeer-technologies-group-bitcoin-sales-october-23/ Mugglehead Media en 2026-10-24T16:19:19.383Z Bitdeer Technologies Group sells all 283.4 BTC in weekly tally NASDAQ: BTDR, NASDAQ: CLSK, Bitdeer Technologies Group, CleanSpark, Inc., Bitcoin mining, Bitcoin treasury, Cash flow